PLI Scheme for Bulk Drugs

Ministry of Chemicals and Fertilizers :

Department of Pharmaceuticals PLI Scheme for Bulk Drugs प्रव तथ: 07 AUG 2026 2:54PM by PIB Delhi 48 projects have been approved under the Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (also known as the PLI Scheme for Bulk Drugs). The scheme has an approved outlay of ₹6,940 crore out of which ₹87.70 crore has been utilized in disbursement of incentive to approved applicants as of March, 2026. Further, production capacity has been created for 28 APIs/KSMs/DIs. Out of these 10 have not achieved commercial production. As of March 2026, cumulative investment of ₹5,070.45 crore has been achieved against a committed investment of ₹4,329.95 crore. The State-wise details of approved projects, committed investment, actual investment made, production capacity approved, capacity created, quantity and value of production achieved and incentive disbursement are placed at Annexure-A.

The list of 41 products approved under PLI scheme for Bulk Drugs is placed at Annexure-B., Out of these, production of following 18 APIs has commenced, thereby reducing import dependency – Penicillin G, Clavulanic Acid, Dexamethasone, Prednisolone, Para Amino Phenol, 1,1 Cyclohexane Diacetic Acid

(CDA), Dicyandiamide (DCDA), Atorvastatin, Levofloxacin, Sulfadiazine, Ofloxacin, Norfloxacin, Artesunate, Telmisartan, Lopinavir, Carbamazepine, Oxcarbazepine and Diclofenac Sodium.

Annexure-A State-wise details of approved projects under PLI Scheme for Bulk Drugs Name of No. of Investment(in crore Capacity (in MT) Production Qty.(in MT) State projects ₹) approved Committed Actual Committed Installed 2023- 2024- 2025- 24 25 26 Andhra 10 1,745.7 2,676 24,390 16,468 224.4 1,207.4 5,498.6 Pradesh Gujarat 8 330.9 407.3 14,270 13,959 7,028.7 4,170 5,572.7 Haryana* 1 81 37 800 NIL NIL NIL NILHimachal 2 806.8 502.6 1,100 400 0.01 69.9 172.1 Pradesh Jammu & 1 185 338.65 1,000 NIL NIL NIL NIL Kashmir* Karnataka 3 96.9 201.4 37 16.7 0 0 0.9 Madhya 2 280 101.8 1,015 15 3.63 4.93 0.32 Pradesh Maharashtra 5 308.4 168.8 40,185 19,180 611.9 500.3 1.14 Punjab 1 137.7 161.1 180 206 91.4 79.6 58.15 Tamil Nadu 2 31.5 45.6 280 280 3.1 0.0025 5.73 Telangana 13 326.02 430.2 7,820 7,820 103.1 89.4 108.03 * Projects in state of Haryana and UT of J&K are under commissioning stage.

Annexure-B Products approved under PLI scheme for Bulk Drugs S. No. Name of KSM/DI/API Key Fermentation based KSMs / Drug Intermediates 1 Penicillin G 2 7-ACA 3 Erythromycin Thiocynate

(TIOC) 4 Clavulanic Acid Fermentation based niche KSMs I Drug Intermediates I APIs 5 Neomycin 6 Gentamycin7 Betamethasone 8 Dexamethasone 9 Prednisolone 10 Rifampicin 11 Vitamin BI 12 Clindamycin Base 13 Streptomycin 14 Tetracycline Key Chemical Synthesis based KSMs I Drug Intermediates 15 1,1 Cyclohexane Diacetic Acid (CDA) 16 2-Methyl-5Nitro-lmidazole (2-MNI) 17 Dicyandiamide (DCDA) 18 Para amino phenol Other Chemical Synthesis based KSMs I Drug Intermediates / APIs 19 Meropenem 20 Atorvastatin 21 Olmesartan 22 Valsartan 23 Losartan 24 Levofloxacin 25 Sulfadiazine26 Ciprofloxacin 27 Ofloxacin 28 Norfloxacin 29 Artesunate 30 Telmisartan 31 Aspirin 32 Diclofenac Sodium 33 Leveti racetam 34 Carbidopa 35 Ritonavir 36 Lopinavir 37 Acyclovir 38 Carbamazepine 39 Oxcarbazepine 40 Vitamin B6 41 Levodopa This information was given by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today.

***** PC/JL (रलीज़ आईडी: 2295928) आगंतुक पटल : 556 इस वज्ञ को इन भाषाओ ंम पढ़: Urdu , ही , Tamil